Peptic Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Peptic Ulcers are open sores that develop on the inside lining of the esophagus, stomach, and the upper portion of the small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes, and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotics, acid blockers, antacids, and proton pump inhibitors.
The Peptic Ulcers pipeline drugs market research report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects.
Peptic Ulcers Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Peptic Ulcers pipeline drugs market are Potassium Transporting ATPase Alpha Chain 1, Prostaglandin G/H Synthase 2, Epidermal Growth Factor Receptor, Histamine H2 Receptor, and Prostaglandin G/H Synthase 1. Potassium Transporting ATPase Alpha Chain 1 leads this segment of the Peptic Ulcers pipeline drugs market.
Peptic Ulcers Pipeline Drugs Market Analysis, by Targets
For more Peptic Ulcers pipeline drugs market target insights, download a free report sample
Peptic Ulcers Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Peptic Ulcers pipeline drugs market are Potassium Transporting ATPase Alpha Chain 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Epidermal Growth Factor Receptor Agonist, Histamine H2 Receptor Antagonist, and Prostaglandin G/H Synthase 1 Inhibitor. Potassium Transporting ATPase Alpha Chain 1 Inhibitor leads the Peptic Ulcers pipeline drugs market in terms of MoA.
Peptic Ulcers Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the Peptic Ulcers pipeline drugs market, download a free report sample
Peptic Ulcers Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Peptic Ulcers pipeline drugs market are oral, parenteral, intravenous, and intravenous drip. Oral leads the Peptic Ulcers pipeline drugs market in terms of RoA.
Peptic Ulcers Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Peptic Ulcers pipeline drugs market, download a free report sample
Peptic Ulcers Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Peptic Ulcers pipeline drugs market are small molecule and fusion protein. Small Molecule leads the Peptic Ulcers pipeline drugs market in terms of molecule types.
Peptic Ulcers Pipeline Drugs Market Analysis, by Molecule Types
For more molecule-type insights into the Peptic Ulcers pipeline drugs market, download a free report sample
Peptic Ulcers Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Peptic Ulcers pipeline drugs market are Jiangsu Carephar Pharmaceutical Co Ltd, Ilyang Pharmaceutical Co Ltd, Addpharma Inc, Axsome Therapeutics Inc, and CalyGene Biotechnology Inc among others. Jiangsu Carephar Pharmaceutical Co Ltd has the highest number of products under development.
Peptic Ulcers Pipeline Drugs Market Analysis, by Companies
To know more about the Peptic Ulcers pipeline drugs market companies, download a free report sample
Peptic Ulcers Pipeline Drugs Market Report Overview
| Key Targets | Potassium Transporting ATPase Alpha Chain 1, Prostaglandin G/H Synthase 2, Epidermal Growth Factor Receptor, Histamine H2 Receptor, and Prostaglandin G/H Synthase 1 |
| Key Mechanisms of Action | Potassium Transporting ATPase Alpha Chain 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Epidermal Growth Factor Receptor Agonist, Histamine H2 Receptor Antagonist, and Prostaglandin G/H Synthase 1 Inhibitor |
| Key Routes of Administration | Oral, Parenteral, Intravenous, and Intravenous Drip |
| Key Molecule Types | Small Molecule and Fusion Protein |
| Key Companies | Jiangsu Carephar Pharmaceutical Co Ltd, Ilyang Pharmaceutical Co Ltd, Addpharma Inc, Axsome Therapeutics Inc, and CalyGene Biotechnology Inc among others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers.
- The pipeline guide reviews pipeline therapeutics for Peptic Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peptic Ulcers therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peptic Ulcers therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Peptic Ulcers
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Peptic Ulcers pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Axsome Therapeutics Inc
CalyGene Biotechnology Inc
Cinclus Pharma AG
Daewoong Co Ltd
FortuneRock (China) Ltd
GL Pharm Tech Corp
Hanmi Pharmaceuticals Co Ltd
Hunan Mingrui Pharmaceutical Co Ltd
Hunan Sailong Pharmaceutical Co Ltd
Ilyang Pharmaceutical Co Ltd
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
JW Pharmaceutical Corp
Korea Pharma Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Onconic Therapeutics Co Ltd
PharmaKing Co Ltd
PharmGen Science Inc
RaQualia Pharma Inc
Shandong New Time Pharmaceutical Co Ltd
Sotex Pharm Firm
Xiamen Encheng Pharmaceutical Co Ltd
XuanZhu Biological Technology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Peptic Ulcers pipeline drugs market?
Some of the targets of the Peptic Ulcers pipeline drugs market are Potassium Transporting ATPase Alpha Chain 1, Prostaglandin G/H Synthase 2, Epidermal Growth Factor Receptor, Histamine H2 Receptor, and Prostaglandin G/H Synthase 1.
-
What are the key mechanisms of action in the Peptic Ulcers pipeline drugs market?
Some of the mechanisms of action of the Peptic Ulcers pipeline drugs market are Potassium Transporting ATPase Alpha Chain 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Epidermal Growth Factor Receptor Agonist, Histamine H2 Receptor Antagonist, and Prostaglandin G/H Synthase 1 Inhibitor.
-
What are the key routes of administration in the Peptic Ulcers pipeline drugs market?
The key routes of administration in the Peptic Ulcers pipeline drugs market are oral, parenteral, intravenous, and intravenous drip.
-
What are the key molecule types in the Peptic Ulcers pipeline drugs market?
The molecule types in the Peptic Ulcers pipeline drugs market are small molecule and fusion protein.
-
Which are the leading companies in the Peptic Ulcers pipeline drugs market?
Some of the leading companies in the Peptic Ulcers pipeline drugs market are Jiangsu Carephar Pharmaceutical Co Ltd, Ilyang Pharmaceutical Co Ltd, Addpharma Inc, Axsome Therapeutics Inc, and CalyGene Biotechnology Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Gastrointestinal reports